{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:08:06Z","timestamp":1791176886243,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["10\/248"],"award-info":[{"award-number":["10\/248"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.vaccine.2014.02.071","type":"journal-article","created":{"date-parts":[[2014,3,23]],"date-time":"2014-03-23T07:46:30Z","timestamp":1395560790000},"page":"2645-2656","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand"],"prefix":"10.1016","volume":"32","author":[{"given":"Tony","family":"Blakely","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgi","family":"Kvizhinadze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Karvonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber L.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.02.071_bib0005","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2165\/11599470-000000000-00000","article-title":"The cost effectiveness of human papillomavirus vaccines: a systematic review","volume":"72","author":"Seto","year":"2012","journal-title":"Drugs"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.02.071_bib0010","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1016\/j.vaccine.2012.06.091","article-title":"Modeling preventative strategies against human papillomavirus-related disease in developed countries","volume":"30","author":"Canfell","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0015","doi-asserted-by":"crossref","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","article-title":"The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia","volume":"29","author":"Smith","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0020","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.vaccine.2013.03.006","article-title":"Estimating the long-term effects of HPV vaccination in Germany","volume":"31","author":"Horn","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0025","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1071\/SH10016","article-title":"Models of cervical screening in the era of human papillomavirus vaccination","volume":"7","author":"Canfell","year":"2010","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0030","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1017\/S0266462311000456","article-title":"Cost-effectiveness of a cervical screening program with human papillomavirus vaccine","volume":"27","author":"Sopina","year":"2011","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0035","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.vaccine.2012.01.001","article-title":"Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening","volume":"30","author":"Coupe","year":"2012","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2014.02.071_bib0040","doi-asserted-by":"crossref","first-page":"B61","DOI":"10.1016\/j.vaccine.2012.11.035","article-title":"The estimated mortality impact of vaccinations forecast to be administered during 2011\u20132020 in 73 countries supported by the GAVI Alliance","volume":"31","author":"Lee","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0045","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1007\/s10552-007-9056-y","article-title":"Racial and ethnic disparities in cervical cancer incidence rates in the United States, 1992\u20132003","volume":"18","author":"McDougall","year":"2007","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0050","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ijc.11141","article-title":"Meta-analysis of social inequality and the risk of cervical cancer","volume":"105","author":"Parikh","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0055","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/1471-2407-8-271","article-title":"Variation in incidence of breast, lung and cervical cancer and malignant melanoma of skin by socioeconomic group in England","volume":"8","author":"Shack","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s10552-011-9804-x","article-title":"Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981\u20131986 to 2001\u20132004","volume":"22","author":"Blakely","year":"2011","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0065","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","article-title":"Annual Report to the Nation on the Status of Cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels","volume":"105","author":"Jemal","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0070","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/jnci\/djs638","article-title":"Inequalities in Human Papillomavirus (HPV)-associated cancers: implications for the success of HPV vaccination","volume":"105","author":"Brisson","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0075","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.vaccine.2013.01.026","article-title":"The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis","volume":"31","author":"Malagon","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0080","first-page":"23","article-title":"HPV vaccination coverage in New Zealand: closing the equity gap","author":"Turner","year":"2011","journal-title":"HPV Today"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0090","doi-asserted-by":"crossref","first-page":"8443","DOI":"10.1016\/j.vaccine.2011.07.096","article-title":"The cost-effectiveness of male HPV vaccination in the United States","volume":"29","author":"Chesson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0095","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1071\/SH10001","article-title":"Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia","volume":"8","author":"Gertig","year":"2011","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0100","series-title":"Burden of Disease Epidemiology, Equity and Cost-Effectiveness (BODE3) study protocol. Version 2.0. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme \u2013 technical report No. XXX","author":"Blakely","year":"2012"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0105","series-title":"Cancer excess mortality rates over 2006\u20132026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme \u2013 technical report No. 10","author":"Blakely","year":"2012"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0110","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","article-title":"Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010","volume":"380","author":"Salomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0115","doi-asserted-by":"crossref","first-page":"532","DOI":"10.2471\/BLT.11.097584","article-title":"Estimating the cost of new public health legislation","volume":"90","author":"Wilson","year":"2012","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0120","doi-asserted-by":"crossref","first-page":"f2032","DOI":"10.1136\/bmj.f2032","article-title":"Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data","volume":"346","author":"Ali","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0125","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1001\/jama.2013.1625","article-title":"Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial","volume":"309","author":"Dobson","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0130","series-title":"CancerTrends: trends in cancer survival by ethnic and socioeconomic group, New Zealand 1991\u20132004","author":"Soeberg","year":"2012"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":"A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0140","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1016\/j.vaccine.2008.06.045","article-title":"The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination","volume":"26","author":"Chesson","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0145","series-title":"Our children's health: key findings on the health of New Zealand children","author":"Ministry of Health","year":"1998"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0150","series-title":"28th international human papillomavirus conference & clinical and public health workshops","article-title":"Impact of HPV vaccination on cost-effectiveness of existing screening programs: example from New Zealand","author":"Canfell","year":"2012"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0155","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1001\/jama.2013.4147","article-title":"Hpv vaccination: too soon for 2 doses?","volume":"309","author":"Kahn Ja","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0160","series-title":"Projected New Zealand lifetables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme (BODE3) \u2013 technical report No. 4","author":"Kvizhinadze","year":"2011"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0165","series-title":"Incorporating ethnic and deprivation variation to cancer incidence estimates over 2006\u20132026 for ABC-CBA. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme \u2013 technical report No. 5","author":"Costilla","year":"2011"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0170","series-title":"National cervical screening programme monitoring report No. 34: 1 July\u201331 December 2010","author":"Smith","year":"2012"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0175","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.vaccine.2007.10.057","article-title":"How much cervical cancer in Australia is vaccine preventable? A meta-analysis","volume":"26","author":"Brotherton","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0180","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1002\/ijc.23282","article-title":"Members of the human papillomavirus type 18 family (alpha-7 species) share a common association with adenocarcinoma of the cervix","volume":"122","author":"Clifford","year":"2008","journal-title":"Int J Cancer J Int Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0185","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1002\/cncr.23758","article-title":"Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods","volume":"113","author":"Watson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0190","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/jmv.20330","article-title":"Human papillomavirus genotypes and their association with cervical neoplasia in a cohort of Western Australian women","volume":"76","author":"Brestovac","year":"2005","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0195","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.bjc.6600688","article-title":"Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis","volume":"88","author":"Clifford","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0200","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1111\/j.1525-1438.2006.00453.x","article-title":"Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia","volume":"16","author":"Stevens","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0205","series-title":"Projected NZ life tables. Burden of Disease Epidemiology, Equity and Cost-Effectiveness Programme \u2013 technical report No. 4","author":"Kvizhinadze","year":"2011"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0210","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.ejca.2006.01.019","article-title":"Survival from rectal and anal cancers in England and Wales, 1986\u20132001","volume":"42","author":"Jeffreys","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.vaccine.2014.02.071_bib0215","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/02841861003691945","article-title":"Trends in the survival of patients diagnosed with cancer in female genital organs in the Nordic countries 1964\u20132003 followed up to the end of 2006","volume":"49","author":"Klint","year":"2010","journal-title":"Acta Oncol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14002989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T15:20:06Z","timestamp":1538752806000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14002989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":43,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0264410X14002989"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.071","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness and equity impacts of three HPV vaccination programmes for school-aged girls in New Zealand","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.02.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}